According to a study over 99% of drug trails for Alzheimer’s disease during the past decade have failed.
US scientists have said there is an urgent need to increase the number of potential therapies being investigated. They say that only one new medicine has been approved since 2004, reports the BBC.
The drug failure rate is troubling and higher than for other diseases such as cancer, says Alzheimer’s Research UK.
Between 2002 and 2012, they found 99.6% of trials of drugs aimed at preventing, curing or improving the symptoms of Alzheimer’s had failed or been discontinued. This compares with a failure rate of 81% for cancer drugs.
The failure rate was “especially troubling” given the rising numbers of people with dementia, said Dr Simon Ridley, of Alzheimer’s Research UK.
“The authors of the study highlight a worrying decline in the number of clinical trials for Alzheimer’s treatments in more recent years,” he said. “There is a danger that the high failure rates of trials in the past will discourage pharmaceutical companies from investing in dementia research. The only way we will successfully defeat dementia is to continue with high quality, innovative research, improve links with industry and increase investment in clinical trials.”
Dr Eric Hill, of the School of Life and Health Sciences at Aston University, said more research was needed to understand the complex mechanisms behind the disease.
“The development of better experimental models that could be incorporated into a battery of tests, will not only help us to understand the changes that occur in the brains of Alzheimer’s disease patients, but also provide tools for the development of new drug treatments that could slow or stop the onset of disease,” he told BBC News.
Introduction The National Statement of Expectations for Supported Housing (NSE) was finally published on 20 October 2020, five years after the 2015 Comprehensive Spending Review suggested regulatory and oversight changes were needed, although in 2018 the government >>>
Responding to the DWP Consultation: Housing Benefit Reform - Supported Housing
"It was well-run, in a good location, and very useful. I've only one suggestion; as the session went on it would perhaps have been useful for bullet points of general agreement about what should be in the sector response to be displayed and added to as the session went on, maybe on a flip chart. Regarding your response paper, I particularly like the answer you give to question 9. In fact the general: "if it ain't broke don't fix it" response could be pushed harder."
M.P. - Adref Ltd